Anbalcabtagene autoleucel(PD-1与TIGIT双敲低CD19 CAR-T)治疗复发或难治性LBCL:CRC01-01试验
Anbalcabtagene autoleucel(anbal-cel)是一种靶向CD19的CAR-T疗法,通过双敲低PD-1和TIGIT增强抗肿瘤功能与持久性。本文报告其治疗复发或难治性大B细胞淋巴瘤的1期和2期研究结果:2期79例接受治疗,73例可评估疗效,完全缓解率67.1%,部分缓解率8.2%,中位无进展生存期6.04个月,中位总生存期未达到。
要点
- 2期可评估73例中,完全缓解率67.1%,部分缓解率8.2%。
- 中位PFS 6.04个月,12个月和18个月OS率分别为66.6%和57.3%。
- 97.5%患者发生≥3级不良事件,最常见为中性粒细胞减少(93.7%)。
核心结论
- Anbal-cel在复发或难治性大B细胞淋巴瘤中显示较高完全缓解率,中位总生存期未达到。
研究设计与样本
- 1期和2期研究,2期79例患者接受anbal-cel,73例评估疗效。
主要发现
- 完全缓解率和部分缓解率分别为67.1%和8.2%。
- 中位无进展生存期为6.04个月(95%CI 4.34-16.46),6、12、18个月PFS率分别为50.9%、41.1%、35.2%。
- 中位总生存期未达到,12个月和18个月OS率分别为66.6%和57.3%。
- 6个月持续完全缓解的长效缓解组CAR+ T细胞上PD-1和TIGIT表达降低。
关键数值与推荐
- 97.5%患者发生≥3级不良事件,中性粒细胞减少93.7%、血小板减少41.8%、贫血30.4%。
- 细胞因子释放综合征发生率57.0%,3级占8.9%,无4级事件。
- 神经系统事件发生率13.9%,≥3级占3.8%。
- 严重感染发生率25.3%,包括3例5级感染。
- 试验注册号NCT04836507。
临床怎么用
- Anbal-cel可作为复发或难治性大B细胞淋巴瘤的一种候选CD19 CAR-T疗法。
- 治疗时需重点监测中性粒细胞减少、血小板减少和贫血等≥3级血液学不良事件。
- 需警惕细胞因子释放综合征和神经系统事件,并关注严重感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anbalcabtagene autoleucel (anbal-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability. We report results from a phase 1 and 2 study in patients with relapsed or refractory large B-cell lymphoma. In phase 2, 79 patients received anbal-cel, and its efficacy was evaluated in 73 patients. The complete response (CR) and partial response rates were 67.1% and 8.2%, respectively. Median progression-free survival (PFS) was 6.04 months (95% confidence interval, 4.34-16.46), and the 6-, 12-, and 18-month PFS rates were 50.9%, 41.1%, and 35.2%, respectively. Median overall survival (OS) was not reached, with 12- and 18-month OS rates of 66.6% and 57.3%, respectively. CAR T-cell expansion (Cmax) was significantly greater in responders than in nonresponders (median Cmax, 20 403 vs 8580 copies per μg). Patients were categorized into long-term response (LR) group or non-LR group based on sustained CR at 6 months. Reduced PD-1 and TIGIT expression on CAR+ T cells was observed in the LR group. Most patients (97.5%) experienced grade ≥3 adverse events, most commonly neutropenia (93.7%), followed by thrombocytopenia (41.8%) and anemia (30.4%). Cytokine release syndrome (CRS) and neurological events occurred in 57.0% and 13.9% of patients, respectively. Grade 3 CRS occurred in 8.9% of patients, with no grade 4 events reported, and grade ≥3 neurological events occurred in 3.8% of patients. Serious infections occurred in 25.3% of patients, including grade 5 infection reported in 3 patients. This trial was registered at www.clinicaltrials.gov as #NCT04836507.
引用
- Kim WS, Kim SJ, Yoon DH, et al. Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial. Blood. 2026. PMID: 42284198. doi:10.1182/blood.2025032636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。